Since targeting glutamine metabolism has been recently recognized as a novel and powerful strategy in cancer therapy [58], including PDAC, several drugs have been developed and introduced in clinical trials targeting glutamine transporters such as the ASCT2(SLC1A5) inhibitor V9302 or the glutaminase-1 (GLS1) inhibitor CB839 [59,60]. This evidence concerns the gene SLC1A5 and cancer.